Myriad Genetics (MYGN) Stock Rating Lowered by TheStreet

Share on StockTwits

Myriad Genetics (NASDAQ:MYGN) was downgraded by TheStreet from a “b” rating to a “c” rating in a report released on Thursday.

A number of other brokerages also recently weighed in on MYGN. Barclays downgraded Myriad Genetics from an “equal weight” rating to an “underweight” rating and lowered their price target for the company from $38.00 to $30.00 in a report on Wednesday, September 5th. BidaskClub upgraded Myriad Genetics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 29th. Zacks Investment Research lowered Myriad Genetics from a “buy” rating to a “sell” rating in a research report on Monday, August 27th. Bank of America boosted their price objective on Myriad Genetics from $31.00 to $34.00 and gave the company a “sell” rating in a research report on Wednesday, August 22nd. Finally, ValuEngine lowered Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 12th. Three analysts have rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $41.90.

Shares of NASDAQ MYGN traded down $0.31 during trading on Thursday, reaching $30.85. The stock had a trading volume of 1,369,527 shares, compared to its average volume of 1,155,791. Myriad Genetics has a one year low of $27.27 and a one year high of $50.44. The company has a current ratio of 3.17, a quick ratio of 2.86 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $2.45 billion, a price-to-earnings ratio of 25.71, a price-to-earnings-growth ratio of 2.02 and a beta of 0.51.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings results on Tuesday, November 6th. The company reported $0.43 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.13. Myriad Genetics had a return on equity of 10.07% and a net margin of 7.07%. The business had revenue of $202.30 million during the quarter, compared to the consensus estimate of $203.20 million. During the same period in the previous year, the business earned $0.26 EPS. The business’s quarterly revenue was up 13.1% on a year-over-year basis. As a group, equities analysts predict that Myriad Genetics will post 1.43 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in MYGN. Robecosam AG boosted its position in Myriad Genetics by 39.8% during the 2nd quarter. Robecosam AG now owns 4,193 shares of the company’s stock worth $156,000 after acquiring an additional 1,193 shares during the period. First Quadrant L P CA acquired a new position in Myriad Genetics during the 3rd quarter worth $201,000. Parametrica Management Ltd acquired a new position in Myriad Genetics during the 3rd quarter worth $204,000. Royal Bank of Canada boosted its position in Myriad Genetics by 59.5% during the 1st quarter. Royal Bank of Canada now owns 4,597 shares of the company’s stock worth $136,000 after acquiring an additional 1,715 shares during the period. Finally, CHICAGO TRUST Co NA acquired a new position in Myriad Genetics during the 3rd quarter worth $230,000. Institutional investors and hedge funds own 96.75% of the company’s stock.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Read More: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.